Type 1 Diabetes Clinical Trials

Several clinical trials for adults with type 1 diabetes are investigating once-weekly insulin options, new treatments for eye complications, and more. You may be able to enroll today.

Diabetes researchers are constantly evaluating new treatments and technologies that could help people with type 1 diabetes live happy and healthier lives. Participating in a clinical trial today can go a long way toward advancing treatments for type 1. You may be able to get involved in several clinical trials looking for participants with type 1 diabetes:

1. Once-Weekly Insulin for Type 1 Diabetes

• A once-weekly insulin option would bring several benefits to people with type 1 diabetes. This study will evaluate the safety and glucose-lowering effect of an investigational once-weekly insulin compared with degludec.

2. Oral Medication for Diabetic Eye Disease

• A clinical trial is recruiting adults with type 1 or type 2 diabetes to investigate a potential oral medication for diabetic retinopathy and other eye complications of diabetes.

More Trials:

ACT1VATE: Addressing Emotional Distress to Improve Outcomes Among Diverse Adults With Type 1 Diabetes

• This study is looking to compare two types of telehealth behavioral support on improving clinical, behavioral, psychosocial, process, and cost outcomes among adults with type 1 diabetes (T1D) who are experiencing significant diabetes-related emotional distress.

IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

• This study is looking to test a new experimental drug (IMCY-0098) that could potentially stop the immune system from attacking insulin-producing cells in people with type 1 diabetes.

Safety Evaluation of an Advanced Hybrid Closed Loop System Using Lyumjev With the Tandem t:Slim X2 Insulin Pump With Control-IQ Technology in Adults, Adolescents and Children With Type 1 Diabetes

• This study, aimed at users of the Tandem t:Slim X2 insulin pump, is looking to evaluate the safety of using an ultra-rapid acting insulin with Tandem's Control-IQ insulin delivery system.

About the authors

Andrew Briskin

Andrew Briskin joined the diaTribe Foundation in 2021 after graduating from the University of Pennsylvania with a degree in Health and Societies . Briskin is an Editor for diaTribe Learn.... Read the full bio »